Intellia announces new data from patients redosed with an investigational in vivo #CRISPR-based therapy at the Peripheral Nerve Society Annual Meeting. Full details here: https://lnkd.in/eGxiDYCm #geneeediting #PNS2024
Intellia Therapeutics, Inc.
Biotechnology Research
Cambridge, Massachusetts 55,044 followers
Developing curative genome editing treatments
About us
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/ .
- Website
-
http://www.intelliatx.com
External link for Intellia Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2014
Locations
-
Primary
40 Erie Street
Cambridge, Massachusetts 02139, US
Employees at Intellia Therapeutics, Inc.
Updates
-
Tomorrow at the International Society on Thrombosis and Haemostasis (ISTH) Congress, Dr. Remy Petersen from Amsterdam University Medical Center will present a poster on Intellia’s investigational #HAE program, titled “Reduction of plasma kallikrein by in vivo CRISPR-based gene editing of KLKB1 does not alter coagulation in patients with #hereditaryangioedema.” Learn more: https://www.isth2024.org/ #ISTH2024
-
Meet Ramsey, a director in Delivery Sciences, Delivery Physics and Biology. He is inspired by his colleagues and the insights they have provided him during his past six years at Intellia. Stay tuned for more employee career journeys this summer! #OneIntellia #IntelliaCareerJourneys
-
Today, we celebrate African-American resilience and the power of progress in honor of #Juneteenth. As we recognize the significance of this historic day, let's continue to strive towards a more equitable future for all.
-
Intellia Vice President, Disease Biology, Sean Burns M.D., will be presenting about Intellia’s #CRISPR #geneediting platform at this week’s Federation of American Societies for Experimental Biology (FASEB) Genome Engineering Conference in Rome, Italy, on June 20. https://lnkd.in/ePhvDw_j #GENESRC
-
Today and every day, we raise a toast to the incredible fathers out there - including the amazing dads at Intellia! ❤️ Let's celebrate and thank them for being our guiding lights. Happy #FathersDay!
-
This week on “Imagine the Possibilities with Intellia,” we speak with Intellia Chief Medical Officer, Dr. David Lebwohl, about his breadth of experience working in the clinical development space. Stream on your favorite podcast platform today! #OneIntellia
-
A warm welcome to Brian Goff, our newest Intellia Board of Directors member, a seasoned global leader focused on rare diseases. Brian brings over three decades of commercialization, operations, sales and marketing experience to our board. More here: https://lnkd.in/eGYEdkSE
-
🎉The 10th anniversary celebration continues with a day of giving back. Volunteering is at the core of who we are, and we take pride in making a positive impact in our local community as we continue working towards making a meaningful impact in the patient community. 🧬 #IntelliaTurns10
-
Intellia is a proud sponsor of this week’s 2024 CASSS – Sharing Science Solutions CGTP Conference. Our colleagues, Jessica Seitzer, VP, Genomics Operations and Kristy Wood, Ph.D., SVP, Technical Operations, are looking forward to presenting on #CRISPR #geneediting. https://lnkd.in/g6G62wwG